Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A

As of June 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A carries a market capitalization of 32.58B, placing it among publicly traded companies globally. Its enterprise value stands at 41.19B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A's next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A has 1.63B shares outstanding.

As of June 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A trades at a trailing price-to-earnings ratio of 13.22. The price-to-sales ratio is 0.42, and the price-to-book ratio stands at 0.83.

As of June 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A trades at an EV/EBITDA multiple of 14.19 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.19 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 41.19B versus a market cap of 32.58B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A maintains a current ratio of 1.65, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 47.10, indicating elevated leverage, while an interest coverage ratio of 7.04 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A posted a return on equity (ROE) of 6.41, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.28 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.94, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.76, useful for judging operating efficiency across full business cycles. The company generates approximately 2.84M in revenue per employee across its workforce of 27,327.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.71 indicates how many times Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A recorded 427.12M in income tax expense. That works out to an effective tax rate of 14.40, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.97B, leaving 2.46B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A's stock has declined approximately 24.09% over the past 52 weeks. The 50-day moving average sits at 20.26, while the 200-day moving average is 22.53.

Over the twelve months ended June 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A generated 77.50B in revenue and converted that into 2.46B in net income, yielding earnings per share of 1.56. EBITDA reached 2.90B, while operating income came in at 2.89B.

As of June 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A holds 13.29B in cash and equivalents against 19.54B in total debt, resulting in a net debt position of 4.37B. Total book value stands at 39.13B, with working capital of 25.40B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A posted a gross margin of 15.60, reflecting its pricing power and cost economics. The operating margin of 3.72 and net profit margin of 3.18 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A paid dividends of 0.97 per share. The dividend payout ratio of 60.13 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -10.73, meaning Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A has an Altman Z-Score of 2.24, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.